Summary
In order to characterise asthma management in a managed care setting. we identified 10 301 patients who were diagnosed with asthma between 1 January 1988 and 31 December 1991 at a group model health maintenance organisation in central Massachusetts, US. We obtained for these patients automated utilisation files containing data on medications, hospitalisations, emergency room visits, office visits, and estimated costs of these services.
The medication dispensed to the greatest proportion of patients was β2 agonists either by inhalation (56%) or orally (21 %). Theophylline was dispensed to 23% of the patients. Maintenance therapy with inhaled anti-inflammatory medication was uncommon, as inhaled corticosteroids (17%) and sodium cromoglycate (cromolyn sodium) [8%] were dispensed to fewer patients than other asthma medications. Among patients who had been hospitalised in the previous year. 36% were presently receiving inhaled corticosteroids. and among patients who used at least one β2 agonist metered-dose inhaler per month, 49% were presently receiving inhaled corticosteroids.
Economic analyses showed that only 8% of the patients had either a hospital admission or an emergency room visit, but hospital costs among these patients accounted for 25% of the total costs of asthma care. In addition, the top 10% most expensive patients accounted for 42% of the total cost of asthma care.
We conclude that a substantial proportion of patients at increased risk of a severe attack. by virtue of having a recent hospitalisation, do not receive maintenance anti-inflammatory therapy, and that hospitalisations among a relatively small proportion of asthma patients contribute significantly to the cost of asthma care.
Similar content being viewed by others
References
Centers for Disease Control. Asthma-United States 1980–1990. MMWR Morb Mortal Wkly Rep 1992; 41: 733–5
National Asthma Education Program Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): Department of Health and Human Services; 1991. Pub. 91-3042
International Classification of Diseases. 9th edition. Salt Lake City, Utah: Medicode, 1994: 30
The Drug Topics Red Book. Montvale (NJ): Medical Economics Data, 1992
Weiss KB, Sullivan SO. The economic costs of asthma. Pharmacoeconomics 1993; 4: 14–30
Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: can it be reduced? Pharmacoeconomics 1993; 3: 205–19
Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992; 326: 862–6
Marion RJ, Creer TL, Reynolds RVC. Direct and indirect costs associated with management of childhood asthma. Ann Allergy 1985; 54: 31–4
Hahn DL, Beasley JW, the Wisconsin Research Network Asthma Prevalence Study Group, et al. Diagnosed and possible undiagnosed asthma: a Wisconsin Research NetworkStUdy. J Fam Pract 1994; 38: 373–9
Skobeloff EM, Spivey WH, St Clair SS, et al. The influence of age and sex on asthma admissions. JAMA 1992: 268: 3437–50
Garrett JE, Lanes SF, Kolbe J, et al. Risk of life-threatening asthma and β-agonist type: an example of confounding byseverity. Thorax. In press
Ernst P, et al. The use of β-agonists and the risk of death and near-death from asthma. N Engl J Med 1992; 326: 501–6
Goetsch M, Greineder D, et al. Pharmacologic management of asthma in the Harvard Community Health Plan [abstract]. Post Mark Surveill 1993: 7: 194–5
Mitchell CA, Henry RL, et al. Asthma morbidity in Australia: an epidemiological study. Med J Aust 1992; 156: 827–31
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lanes, S.F., Birmann, B.M., Walker, A.M. et al. Characterisation of Asthma Management in the Fallon Community Health Plan from 1988 to 1991. Pharmacoeconomics 10, 378–385 (1996). https://doi.org/10.2165/00019053-199610040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199610040-00006